MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, has launched new technology and expanded capacity to advance ADC therapies. MilliporeSigma continues to invest in novel modalities and support the company’s efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future.   “ADCs have experienced remarkable growth, with commercially approved ADCs tripling in the past three years,” said ...